The DOI matches its Crossref record; 141 of the 141 references it cites were found in a registry or an index.
Cancer Therapy–Induced Cardiac Toxicity in Early Breast Cancer: Addressing the Unresolved Issues
Open accessAbstract
landscape of early breast cancer has changed dramat- ically with significant advancements in early screening and diagnosis and curative-intent therapies.Indeed, breast cancer-specific survival has improved by 20% during the past 30 years, and 5-year survival is now 98% for early-stage disease. 1 As a consequence, the risk and nature of adjuvant therapy-induced immediate and late-occurring cardiovascular injury have similarly evolved.In women with early breast cancer, particularly those Ͼ65 years of age, cardiovascular disease (CVD) is now the predominant cause of mortality as indicated by Surveillance, Epidemiology, and End Results (SEER)-Medicare linked data. 2 Additionally, these women are also at increased risk of CVD compared with age-matched women without a history of breast cancer. 3ignificant cardiac safety concerns about anticancer therapy were first described by Von Hoff and colleagues, 4 identifying dose-dependent and progressive left ventricular (LV) dysfunction manifesting as symptomatic heart failure in patients receiving anthracyclines.From this work and others, 5,6 anthracycline-induced cardiac toxicity 7,8 is now a well-recognized adverse side effect.More recently, randomized trials have demonstrated that human epidermal growth factor receptor 2 (HER2)-directed monoclonal antibodies (ie, trastuzumab) and newer multitargeted small-molecule inhibitors interfere with molecular pathways crucial to normal cardiac homeostasis, 9 resulting in relatively high incidences of subclinical and overt cardiac toxicity. 10Although cardiac toxicity with newer therapies has demonstrated reversibility, 11 recovery of LV function after treatment cessation is uncertain at this time. 12Thus, to identify those individuals at high risk of cardiac toxicity, baseline measurement of LV ejection fraction (LVEF) is recommended by the American College of Cardiology (ACC) and American Heart Association (AHA) as standard of care for all breast cancer patients being considered for potentially cardiac-toxic treatment regimens. 13,14In addition, measurement of LVEF is Food and Drug Administration (FDA) mandated in all registrational breast cancer adjuvant trials involving an anthracycline-or a trastuzumab-containing regimen.Finally, use of endocrine therapy (eg, tamoxifen and aromatase inhibitors) in women with hormone receptor-positive breast cancer may also increase the risk of cardiovascular complications. 15espite the rapidly changing landscape of breast cancer management and the resultant changes in cardiovascular safety, several critical issues in the emerging field of "cardiooncology" remain unresolved.To ensure that this field keeps pace, a full understanding of the incidence, magnitude, and consequences of cardiovascular side effects of adjuvant therapy is an essential first step in optimizing early breast cancer management.Against this background, the purpose of this article is to comprehensively review several pivotal unaddressed issues concerning the definition, incidence, detection, and clinical importance of cardiac toxicity in early breast cancer.The evidence supporting the efficacy of preventive and treatment strategies is also discussed.In this article, we use the term cardiac toxicity to refer to myocardial injury related to anticancer pharmacological therapies.The principal manifestations of myocardial injury, LV dysfunction and heart failure, are the primary focus of our review.Additional cardiovascular toxicities associated with anticancer therapies, including sequelae of vascular injury (ie, myocardial ischemia/infarction and stroke), are also considered in discussions of CVD events.Finally, the range of potential cardiovascular effects of currently approved adjuvant breast cancer systemic therapies is summarized and highlighted by class of agent in Table 1. Definition and Clinical ImportanceSeveral oncology and cardiology organizations provide definitions for cardiac toxicity that encompass overt clinical events and subclinical injury (Table 2), although there is no universally accepted definition or clinical cut points.In registrational oncology trials, the most widely adopted criteria for adjudicating cardiovascular events is the Common Terminology Criteria for Adverse Events, developed by the National Cancer Institute. 17,18The Common Terminology
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,778
Cell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774
2005 WRITING COMMITTEE MEMBERS, Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192065 · Cited by 3,720
The National Comprehensive Cancer Network (NCCN).
Wood, E. H. (2004) · Journal of the Medical Library Association JMLA · Cited by 2,841
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., Mackey, J., Glaspy, J., Chan, A., Pawlicki, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910383 · Cited by 2,775
Self-citationRisk Factors for Doxorubicin-lnduced Congestive Heart Failure
VON HOFF, D. D., LAYARD, M. W., BASA, P., DAVIS, H. L., VON HOFF, A. L., ROZENCWEIG, M., & MUGGIA, F. M. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-5-710 · Cited by 2,391
Swain, S. M., Whaley, F. S., & Ewer, M. S. (2003) · Cancer · doi:10.1002/cncr.11407 · Cited by 2,313
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji237 · Cited by 2,162
Cited by
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw211 · Cited by 2,544
Thavendiranathan, P., Poulin, F., Lim, K.-D., Plana, J. C., Woo, A., & Marwick, T. H. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.073 · Cited by 1,079
Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., Ganame, J., Sebag, I. A., Agler, D. A., Badano, L. P., et al. (2014) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeu192 · Cited by 1,058
Self-citationMehta, L. S., Watson, K. E., Barac, A., Beckie, T. M., Bittner, V., Cruz-Flores, S., Dent, S., Kondapalli, L., Ky, B., Okwuosa, T., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000556 · Cited by 848
Farmakis, D., Parissis, J., & Filippatos, G. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.026 · Cited by 387
Metadata
- Authors
- Khouri, M. G., Douglas, P. S., Mackey, J. R., Martin, M., Scott, J. M., Scherrer-Crosbie, M., & Jones, L. W.
- Venue
- Circulation
- Published
- 2012-12-04
- Volume
- 126
- Issue
- 23
- Pages
- 2749-2763
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2126727347
- Cited by
- 255
- References
- 141
- FWCI
- 8.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cancer Therapy–Induced Cardiac Toxicity in Early Breast Cancer: Addressing the Unresolved Issues. https://app.cochat.ai/papers/10.1161/circulationaha.112.100560
- The paper
- Khouri, M. G., Douglas, P. S., Mackey, J. R., Martin, M., Scott, J. M., Scherrer-Crosbie, M., & Jones, L. W. (2012). Cancer Therapy–Induced Cardiac Toxicity in Early Breast Cancer: Addressing the Unresolved Issues. Circulation. https://doi.org/10.1161/circulationaha.112.100560
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.